Cognitive Processing Therapy Shows Superior Efficacy for PTSD Treatment in Landmark Japanese Study
• A 16-week clinical trial demonstrated that cognitive processing therapy combined with standard treatment significantly reduced PTSD symptoms compared to usual care alone in Japanese patients.
• The study, conducted at a Tokyo psychiatric hospital, showed a marked decrease in CAPS-5 scores from 35.97 to 22.36 in the CPT group, while control group scores remained largely unchanged.
• Beyond PTSD improvement, patients receiving cognitive processing therapy showed significant positive changes in depression, suicidal ideation, and overall disability measures, with no serious adverse events reported.
L-Arginine Shows Promise but Falls Short of Statistical Significance in Spinocerebellar Ataxia Type 6 Trial
• A Phase 2 trial of L-arginine in Spinocerebellar Ataxia type 6 (SCA6) showed a trend toward symptom improvement, but the results did not reach statistical significance.
• The L-arginine group experienced a 0.96-point improvement in SARA scores, while the placebo group worsened by 0.56 points over 48 weeks.
• Two serious adverse events potentially linked to L-arginine were reported, including one fatality due to pneumonia and one case of reversible liver impairment.
• Further Phase 3 trials with larger cohorts are needed to confirm L-arginine's efficacy and safety in treating SCA6, a neurodegenerative disorder.
© Copyright 2025. All Rights Reserved by MedPath